2019新型冠状病毒感染潜在抗病毒治疗药物

2019新型冠状病毒(2019 novel coronavirus,2019-nCoV)感染是一种新发、突发传染性疾病,传染性强[1],2019-nCoV与严重急性呼吸综合征相关冠状病毒(SARS-CoV)和中东呼吸综合征相关冠状病毒(MERS-CoV)近缘,均可引起重症肺炎、呼吸衰竭和多器官功能障碍。由该病毒感染引起的疾病被称为2019冠状病毒肺炎(corona virus disease 2019,COVID-19),目前针对2019-nCoV尚无特异抗病毒药物。基因组研究表明,2019-nCoV与SARS-CoV、MERS-CoV分别有79%和50%的基因序列相似性[2],推测SARS-CoV、MERS-CoV中的抗病毒治疗经验及证据对于2019-nCoV有一定借鉴意义。为更好地协助一线临床医师开展救治工作,本文针对2019-nCoV的防控方案及既往SARS-CoV、MERS-CoV的诊疗方案、专家共识和指南,对目前6种可供选择的抗病毒药物(干扰素α、利巴韦林、洛匹那韦/利托那韦、瑞德西韦、阿比多尔及氯喹/羟氯喹)研究进行综述,其中瑞德西韦在我国正展开Ⅲ期临床试验,另外5种已在国内上市的药物针对2019-nCoV的抗病毒疗效尚未明确。

Potential Antiviral Drugs in the Treatment of Corona Virus Disease 2019

Since December 2019, a new pneumonia of 2019-nCoV cause broke out in Wuhan City, and the infection has spread rapidly in China and worldwide. The virus is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia, respiratory failure, multisystem organ failure, or even death. This outbreak shaped tremendous challenges to Chinese public health and clinical treatment. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research. After the outbreak of this disease, China immediately launched national level 1 response and Chinese scientists invested a lot of energy to carry out research by developing antiviral drugs, vaccines and rapid diagnostic reagents, ect. In order to assist the doctors in defeating this pestilence, we reviewed the available antiviral drugs, based on the current guidelines for 2019-nCoV and previous reports of SARS-CoV and MERS-CoV.